EZH2 knockdown in SMARCB1 deficient ecMRT tumors decreased the tumor growth rate,100 while targeting EZH2 with Ribavirin101 or DZNep102 led to increased survival in orthotopic AT/RT xenograft models. Here, SMARCB1 is linked to neoplasm.